Mylan receives FDA approval for generic version of Risperdal

Mylan Inc today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone Tablets USP, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.

Risperidone Tablets, used to treat schizophrenia and bipolar disorder, are the generic version of Janssen's Risperdal(R) Tablets. This product had annual U.S. sales of approximately $2.67 billion for the 12 months ending June 30, 2008, for the noted strengths, according to IMS Health.

Mylan will ship the product shortly. Currently, the company has 109 ANDAs pending FDA approval, 22 of which are potential first-to-file opportunities.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ultra-processed food linked to weight gain and lower well-being in adolescents